Bamco Inc. NY Purchases New Shares in West Pharmaceutical Services, Inc. $WST

Bamco Inc. NY purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 164,174 shares of the medical instruments supplier's stock, valued at approximately $58,938,000. Bamco Inc. NY owned approximately 0.23% of West Pharmaceutical Services as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Empowered Funds LLC raised its position in shares of West Pharmaceutical Services by 16.1% during the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier's stock worth $361,000 after purchasing an additional 224 shares during the last quarter. Intech Investment Management LLC boosted its holdings in West Pharmaceutical Services by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier's stock worth $1,348,000 after buying an additional 1,307 shares during the last quarter. Acadian Asset Management LLC increased its stake in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier's stock worth $284,000 after buying an additional 157 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of West Pharmaceutical Services by 78.2% during the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier's stock valued at $98,000 after acquiring an additional 197 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of West Pharmaceutical Services by 168.4% during the second quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier's stock valued at $10,137,000 after acquiring an additional 29,067 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on WST shares. Zacks Research cut West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. Morgan Stanley raised their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an "equal weight" rating in a report on Thursday, July 9th. TD Cowen reaffirmed a "buy" rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a report on Monday, July 13th. They set an "outperform" rating and a $447.00 target price for the company. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of "Moderate Buy" and an average target price of $368.08.

West Pharmaceutical Services Stock Up 0.6%

NYSE WST opened at $350.68 on Thursday. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The business's fifty day simple moving average is $349.99 and its 200-day simple moving average is $302.68. The firm has a market cap of $24.68 billion, a PE ratio of 44.90, a P/E/G ratio of 2.44 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the prior year, the firm posted $1.84 earnings per share. West Pharmaceutical Services's quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services's payout ratio is currently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source